- Previous Close
141.76 - Open
141.08 - Bid 142.26 x 900
- Ask 143.03 x 300
- Day's Range
141.08 - 145.21 - 52 Week Range
113.50 - 211.13 - Volume
537,172 - Avg. Volume
710,035 - Market Cap (intraday)
7.988B - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date Feb 19, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
192.25
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
www.repligen.com1,783
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Medical Instruments & Supplies
Industry
Recent News: RGEN
View More
Performance Overview: RGEN
Trailing total returns as of 2024-11-22, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGEN
View MoreValuation Measures
Market Cap
7.99B
Enterprise Value
7.88B
Trailing P/E
466.37
Forward P/E
89.29
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.46
Price/Book (mrq)
3.96
Enterprise Value/Revenue
12.31
Enterprise Value/EBITDA
75.05
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.33%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
639.92M
Net Income Avi to Common (ttm)
-2.11M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
809.15M
Total Debt/Equity (mrq)
37.40%
Levered Free Cash Flow (ttm)
--